Positive CHMP opinion sets stage for GSK’s ready-to-use Shingrix syringe approval in Europe

GSK plc (LSE: GSK, NYSE: GSK) has received a key regulatory boost with the European Medicines Agency’s Committee for Medicinal Products for Human Use issuing a positive opinion in support of a new prefilled syringe presentation for Shingrix, the British pharmaceutical major’s recombinant zoster vaccine. The regulatory committee’s endorsement brings GSK plc closer to full European Commission marketing authorisation, which is expected by December 2025. The development is expected to significantly simplify vaccine delivery workflows across Europe, where shingles affects an estimated 1.7 million people annually.

The new formulation will allow healthcare professionals to administer Shingrix without the need to mix two separate vials. Currently, the vaccine is provided as a lyophilised antigen powder and a liquid adjuvant, which must be combined manually prior to injection. The new ready-to-use format eliminates this step entirely, reducing preparation time, lowering the risk of error, and improving throughput in busy clinical environments.

In a statement, GSK plc’s Chief Scientific Officer Tony Wood underscored that the company’s innovation efforts continue to be centred around both immunological efficacy and real-world delivery improvements. He noted that the shift to a prefilled format reflects the British pharmaceutical company’s intent to reduce complexity for frontline healthcare workers while ensuring broader protection against shingles, particularly among Europe’s ageing population.

Why are prefilled syringes being positioned as the next frontier in vaccine delivery?

For a disease like shingles, where timely administration can make a meaningful difference in outcomes, the efficiency of vaccine delivery systems is a critical public health variable. The prefilled syringe format removes a procedural barrier that has historically slowed down immunisation efforts in some healthcare settings. GSK plc stated that the CHMP’s decision was based on analytical and clinical comparability data demonstrating equivalence between the new format and the existing two-vial configuration.

Shingrix, originally launched in the European Union in 2018 for adults aged 50 years and older, was later extended in 2020 to include adults over 18 who are at heightened risk of herpes zoster. The recombinant zoster vaccine has since become a staple in immunisation programs globally, largely due to its efficacy profile and targeted design for ageing or immunocompromised populations. By combining the glycoprotein E antigen with the AS01B adjuvant system, Shingrix was engineered to address the natural immune system decline associated with age, making it a preferred option over older-generation zoster vaccines.

Prefilled syringes have gained traction in both public and private healthcare sectors due to their ability to reduce dosing errors, improve standardisation, and streamline cold-chain logistics. For GSK plc, the launch of this new presentation marks a continuation of its broader push into smart vaccine platforms that blend clinical performance with delivery innovation.

What does this mean for the European shingles vaccination landscape?

Shingles, or herpes zoster, is caused by the reactivation of latent varicella-zoster virus—the same virus responsible for childhood chickenpox. It manifests as a painful rash often appearing on the chest, abdomen, or face, with some cases leading to post-herpetic neuralgia, a chronic neuropathic pain condition that can last for months or even years. According to published literature, up to 30 percent of shingles patients experience this prolonged nerve pain, which in turn leads to increased medical visits, lost productivity, and decreased quality of life.

In Europe, shingles represents not only a healthcare challenge but also a rising economic burden as the population continues to age. With over 90 percent of adults estimated to carry the dormant varicella-zoster virus, healthcare systems are under increasing pressure to implement preventive vaccination strategies. GSK plc’s recombinant zoster vaccine has emerged as a primary solution to this challenge, and the addition of a prefilled syringe is expected to further ease integration into immunisation programs.

According to the British pharmaceutical company, the disease’s healthcare cost footprint is not trivial. Patients with shingles reportedly take an average of 12.5 days off work, while those with post-herpetic neuralgia may be on sick leave for as long as two months. These metrics underline why simplifying the vaccination process could have meaningful downstream benefits for both healthcare infrastructure and national economies.

How does the prefilled syringe format align with GSK’s vaccine innovation strategy?

GSK plc has consistently emphasised its strategy of delivering high-efficacy vaccines through platforms that are practical, scalable, and globally accessible. The prefilled syringe presentation of Shingrix is a direct extension of this approach. In addition to convenience, the format enhances cold-chain integrity, reduces risk of reconstitution errors, and can accelerate mass immunisation timelines—critical for outbreaks or seasonal spikes in demand.

The British pharmaceutical major’s leadership, particularly under Chief Executive Officer Emma Walmsley, has worked to refocus the company’s pipeline on specialty therapeutics and high-margin vaccines following the demerger of consumer health spin-off Haleon plc. Vaccines remain a core growth pillar, and innovations such as this are seen as instrumental in defending market share and securing new country-level procurement deals.

GSK plc has also invested heavily in its global vaccine manufacturing network and digital integration tools, ensuring that its platforms remain adaptable to new regulatory expectations, supply chain challenges, and real-time demand planning. The upcoming European Commission decision on the Shingrix prefilled syringe is expected to be a straightforward process, with no additional efficacy data required due to the confirmed technical comparability.

How are analysts and institutional investors viewing GSK’s shingles portfolio in 2025?

Market reaction to the CHMP update was neutral to moderately positive, with GSK plc shares (LSE: GSK) trading relatively flat on the London Stock Exchange following the announcement. However, institutional sentiment remains supportive of the company’s broader vaccines narrative. Buy-side analysts noted that while the prefilled syringe does not represent a blockbuster-level inflection, it reinforces the British pharmaceutical company’s image as an execution-focused innovator.

The shingles vaccine continues to deliver robust revenues, particularly in ageing economies and immunocompromised segments. Analysts expect that adoption of the prefilled format could drive additional uptake in primary care and high-volume clinic settings, where efficiency is paramount. Some forecast a modest uptick in market share for GSK plc in countries where physician convenience heavily influences vaccine selection.

In terms of financial modelling, most institutions have already embedded sustained Shingrix revenue into their projections, but the operational benefits of the new format could result in margin expansion on the distribution and packaging side. That said, near-term share price movement is likely to be driven more by upcoming oncology and respiratory pipeline catalysts than vaccine presentation updates.

What are the next steps and potential timelines for rollout across the EU?

GSK plc expects formal marketing authorisation from the European Commission in December 2025, following the CHMP’s positive opinion. If approved, the prefilled syringe format could begin rollout in key EU markets in early 2026. The British pharmaceutical company will likely prioritise distribution to high-incidence geographies and coordinate with national immunisation programs to integrate the new format into existing procurement and reimbursement structures.

The company did not disclose whether additional filings for the prefilled syringe presentation have been made in the United States or other global markets. However, given GSK plc’s global shingles vaccine footprint, expansion into North America, Asia-Pacific, and Latin America remains a strategic possibility once EU deployment is stabilised.

The current shingles vaccination infrastructure in the EU is mature, but still faces gaps in coverage among at-risk populations, especially those under age 60 with comorbidities. The British pharmaceutical company’s move to lower logistical barriers with the prefilled Shingrix format may help close this gap and solidify its leadership in adult immunisation across Europe.

Key takeaways: What the positive CHMP opinion means for GSK’s Shingrix vaccine rollout

• GSK plc has received a positive CHMP opinion for its recombinant zoster vaccine Shingrix in a prefilled syringe presentation, paving the way for EU approval by December 2025.

• The new format eliminates the need to mix two vials, offering a ready-to-use solution that simplifies administration and reduces preparation errors for healthcare providers.

• Shingrix has already been approved in the European Union since 2018 for adults aged 50+, and since 2020 for high-risk adults aged 18 and above.

• The CHMP’s support is based on data confirming technical and immunogenic equivalence between the prefilled syringe and existing dual-vial formats.

• Shingles affects approximately 1.7 million people annually in Europe, with 30% of cases resulting in long-term nerve pain (PHN) that can impact work and quality of life.

• Analysts view the new format as an incremental but operationally important catalyst, potentially increasing adoption in primary care clinics and high-volume settings.

• GSK plc expects formal European Commission marketing authorisation in December 2025, with EU-wide rollout of the new syringe format expected in early 2026.

• Institutional investor sentiment around GSK’s vaccines segment remains stable and supportive, with Shingrix continuing to serve as a core revenue contributor post-Haleon spin-off.